Acalnib 100mg Capsules: Product Overview
Acalnib 100mg Capsules contain acalabrutinib 100mg, a targeted anticancer medicine belonging to the Bruton’s tyrosine kinase (BTK) inhibitor class. It is used under specialist medical supervision for certain types of B-cell blood cancers. Healthcare professionals and pharmaceutical procurement teams seeking information about Acalnib 100mg Capsules can review the product details and applicable regulatory requirements before making supply enquiries.
Cordium Pharmaceuticals Pvt Ltd, an India-based pharmaceutical supplier and exporter specialising in oncology medicines, provides product information and supports professional enquiries regarding pharmaceutical sourcing, subject to product availability and destination-country regulations.
Product Details of Acalnib 100mg Capsules
Product name: Acalnib 100mg Capsules
Active ingredient: Acalabrutinib
Strength: 100mg
Dosage form: Oral capsule
Therapeutic category: Targeted anticancer medicine
Drug class: BTK inhibitor
Supply status: Subject to applicable prescription, licensing and import requirements
Product identity, manufacturer details, packaging and regulatory documentation should be verified against the specific product being sourced. UK buyers should confirm the medicine’s authorisation status before considering procurement.
What Is Acalnib 100mg Used For?
Acalabrutinib is prescribed for certain B-cell malignancies, including chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and, in specified clinical circumstances, mantle cell lymphoma (MCL). The authorised indications depend on the applicable product licence and clinical circumstances.
Acalabrutinib works by inhibiting BTK, a protein involved in B-cell receptor signalling. Blocking this pathway can interfere with signals that help certain abnormal B cells survive and multiply.
Treatment decisions must be made by a qualified oncology specialist. The medicine is not suitable for every patient, and its use should follow the relevant prescribing information. Patients must not start treatment or change their prescribed dose without medical advice.
Potential Side Effects of Acalnib 100mg
Like other targeted cancer medicines, acalabrutinib can cause side effects. Reported effects may include:
Headache
Diarrhoea
Muscle or joint pain
Fatigue
Nausea
Bruising or bleeding
Increased susceptibility to infections
More serious risks can include significant bleeding, serious infections, changes in blood counts and heart rhythm problems. Individual risks vary according to medical history, other medicines and treatment circumstances.
Patients should promptly contact their oncology team about concerning symptoms. Severe bleeding, chest pain, fainting or signs of a serious infection require urgent medical assessment. The prescribing information should be consulted for complete safety information and potential drug interactions.
Acalnib 100mg Supply Enquiries for the UK
Cordium Pharmaceuticals Pvt Ltd welcomes professional enquiries concerning oncology product information and potential pharmaceutical supply arrangements from India to the UK. Healthcare organisations, licensed distributors and authorised procurement professionals should confirm product availability, manufacturer details, documentation, shipping conditions and applicable import permissions before proceeding.
Acalnib 100mg should not be purchased from unverified online sellers. UK medicine supply is subject to strict regulatory controls, and prescription medicines should be obtained through appropriate authorised channels.
Frequently Asked Questions
1. What is the active ingredient in Acalnib 100mg Capsules?
The product is identified as containing acalabrutinib 100mg. Verify the composition against the actual packaging and product documentation.
2. What conditions can acalabrutinib treat?
Depending on the authorised indication, it may be prescribed for certain B-cell blood cancers, including CLL, SLL and MCL.
3. Can Acalnib 100mg be purchased online in the UK?
Patients should consult their oncology specialist and obtain prescribed medicines through legally authorised UK channels. Professional supply enquiries must comply with applicable medicines and import regulations.
4. How can professional buyers contact Cordium Pharmaceuticals?
Professional buyers can contact Cordium Pharmaceuticals Pvt Ltd through its official website to enquire about product documentation, availability and compliant supply arrangements.
Medical disclaimer: This article is for general educational and professional product-information purposes. It does not replace medical advice, prescribing information or regulatory guidance.
Acalnib 100mg Capsules contain acalabrutinib 100mg, a targeted anticancer medicine belonging to the Bruton’s tyrosine kinase (BTK) inhibitor class. It is used under specialist medical supervision for certain types of B-cell blood cancers. Healthcare professionals and pharmaceutical procurement teams seeking information about Acalnib 100mg Capsules can review the product details and applicable regulatory requirements before making supply enquiries.
Cordium Pharmaceuticals Pvt Ltd, an India-based pharmaceutical supplier and exporter specialising in oncology medicines, provides product information and supports professional enquiries regarding pharmaceutical sourcing, subject to product availability and destination-country regulations.
Product Details of Acalnib 100mg Capsules
Product name: Acalnib 100mg Capsules
Active ingredient: Acalabrutinib
Strength: 100mg
Dosage form: Oral capsule
Therapeutic category: Targeted anticancer medicine
Drug class: BTK inhibitor
Supply status: Subject to applicable prescription, licensing and import requirements
Product identity, manufacturer details, packaging and regulatory documentation should be verified against the specific product being sourced. UK buyers should confirm the medicine’s authorisation status before considering procurement.
What Is Acalnib 100mg Used For?
Acalabrutinib is prescribed for certain B-cell malignancies, including chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and, in specified clinical circumstances, mantle cell lymphoma (MCL). The authorised indications depend on the applicable product licence and clinical circumstances.
Acalabrutinib works by inhibiting BTK, a protein involved in B-cell receptor signalling. Blocking this pathway can interfere with signals that help certain abnormal B cells survive and multiply.
Treatment decisions must be made by a qualified oncology specialist. The medicine is not suitable for every patient, and its use should follow the relevant prescribing information. Patients must not start treatment or change their prescribed dose without medical advice.
Potential Side Effects of Acalnib 100mg
Like other targeted cancer medicines, acalabrutinib can cause side effects. Reported effects may include:
Headache
Diarrhoea
Muscle or joint pain
Fatigue
Nausea
Bruising or bleeding
Increased susceptibility to infections
More serious risks can include significant bleeding, serious infections, changes in blood counts and heart rhythm problems. Individual risks vary according to medical history, other medicines and treatment circumstances.
Patients should promptly contact their oncology team about concerning symptoms. Severe bleeding, chest pain, fainting or signs of a serious infection require urgent medical assessment. The prescribing information should be consulted for complete safety information and potential drug interactions.
Acalnib 100mg Supply Enquiries for the UK
Cordium Pharmaceuticals Pvt Ltd welcomes professional enquiries concerning oncology product information and potential pharmaceutical supply arrangements from India to the UK. Healthcare organisations, licensed distributors and authorised procurement professionals should confirm product availability, manufacturer details, documentation, shipping conditions and applicable import permissions before proceeding.
Acalnib 100mg should not be purchased from unverified online sellers. UK medicine supply is subject to strict regulatory controls, and prescription medicines should be obtained through appropriate authorised channels.
Frequently Asked Questions
1. What is the active ingredient in Acalnib 100mg Capsules?
The product is identified as containing acalabrutinib 100mg. Verify the composition against the actual packaging and product documentation.
2. What conditions can acalabrutinib treat?
Depending on the authorised indication, it may be prescribed for certain B-cell blood cancers, including CLL, SLL and MCL.
3. Can Acalnib 100mg be purchased online in the UK?
Patients should consult their oncology specialist and obtain prescribed medicines through legally authorised UK channels. Professional supply enquiries must comply with applicable medicines and import regulations.
4. How can professional buyers contact Cordium Pharmaceuticals?
Professional buyers can contact Cordium Pharmaceuticals Pvt Ltd through its official website to enquire about product documentation, availability and compliant supply arrangements.
Medical disclaimer: This article is for general educational and professional product-information purposes. It does not replace medical advice, prescribing information or regulatory guidance.
Keywords
